Antibodies to cyclic citrullinated peptide (anti-CCP), CRP, other inflammatory markers levels, and initial radiographic damage are currently used to distinguish patients at greatest risk for increasing progressive bone destruction, in order to achieve aggressive treatment strategies in designated group of RA patients [36, 37]. Here, CRP is linked to rheumatoid arthritis.